Читать книгу Pharma and Profits - John L. LaMattina - Страница 2

Оглавление

1 Cover
2 Title Page
3 Copyright Page
4 Dedication
5 ACKNOWLEDGMENTS
6 INTRODUCTION REFERENCES
7 CHAPTER 1: THE $1000 PILL REFERENCES
8 CHAPTER 2: ENTER THE PAYERS REFERENCES
9 CHAPTER 3: PANDEMIC REFERENCES
10 CHAPTER 4: FEDERAL INVESTMENT IN R&D REFERENCES
11 CHAPTER 5: INSULIN REFERENCES
12 CHAPTER 6: THE COSTLY ALZHEIMER’S DISEASE DRUG REFERENCES
13 CHAPTER 7: GENE THERAPY REFERENCES
14 CHAPTER 8: PROVING THE VALUE OF EXPENSIVE DRUGS REFERENCES
15 CHAPTER 9: GENERIC DRUGS REFERENCES
16 CHAPTER 10: ABOUT THOSE SOARING PHARMA PROFITS REFERENCES
17 CHAPTER 11: SCHEMES TO LOWER DRUG PRICES REFERENCES
18 FINAL THOUGHTS REFERENCES
19 Index
20 End User License Agreement

List of Tables

1 Chapter 3TABLE 3.1 mRNA timeline for Moderna and Pfizer

List of Illustrations

1 Chapter 5Graph 5.1 Lantus cost over time.
2 Chapter 7Figure 7.1 Competition of spinal muscular atrophy drugs.
3 Chapter 10Figure 10.1 Healthcare spending 2003–2018.

Guide

1 Cover Page
2 Title Page
3 Copyright Page
4 Dedication
5 ACKNOWLEDGMENTS
6 INTRODUCTION
7 Table of Contents
8 Begin Reading
9 FINAL THOUGHTS
10 Index
11 WILEY END USER LICENSE AGREEMENT

Pages

1 iii
2 iv
3 v
4 ix
5 x
6 xi
7 xii
8 1
9 2
10 3
11 4
12 5
13 6
14 7
15 8
16 9
17 10
18 11
19 12
20 13
21 14
22 15
23 16
24 17
25 18
26 19
27 20
28 21
29 22
30 23
31 24
32 25
33 26
34 27
35 28
36 29
37 30
38 31
39 32
40 33
41 34
42 35
43 36
44 37
45 38
46 39
47 40
48 41
49 42
50 43
51 44
52 45
53 46
54 47
55 48
56 49
57 50
58 51
59 52
60 53
61 54
62 55
63 56
64 57
65 58
66 59
67 60
68 61
69 62
70 63
71 64
72 65
73 66
74 67
75 68
76 69
77 70
78 71
79 72
80 73
81 74
82 75
83 76
84 77
85 78
86 79
87 80
88 81
89 82
90 83
91 84
92 85
93 86
94 87
95 88
96 89
97 90
98 91
99 92
100 93
101 94
102 95
103 96
104 97
105 98
106 99
107 100
108 101

Подняться наверх